Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. The firm markets several key therapeutic agents, including Fetroja, a crucial therapy for multi-drug resistant gram-negative bacterial infections; Xofluza, an antiviral medication for influenza; and Tivicay, an effective anti-HIV agent. Shionogi also maintains an extensive research and development pipeline, with numerous compounds under investigation for various conditions. Its development portfolio includes treatments for opioid-induced constipation (Symproic), various pain types such as inflammatory pain (S-120083), neuropathic pain (S-010887, sivopixant), and neuropathic low back pain (S-637880). Sivopixant is additionally being explored for sleep apnea syndrome and refractory/unexplained chronic cough. In neuroscience, the company is advancing S-117957 for insomnia, Zuranolone for depression, SDT-001 for attention-deficit/hyperactivity disorder, and BPN14770 for Fragile X syndrome and Alzheimer's disease. Furthermore, it is developing S-237648 and S-309309 as potential obesity treatments. In oncology and hepatology, ADR-001 addresses decompensated liver cirrhosis, and S-723595 targets NASH. Multiple anti-cancer compounds are in development, including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 and S-531011 for solid tumors, and S-222611 for malignant tumors. Other experimental therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. Addressing the ongoing pandemic, Shionogi is also advancing S-600918 and S-217622 for COVID-19, with S-555739 specifically aimed at preventing the aggravation of the disease. Beyond therapeutics, it supplies antibody test kits for COVID-19. The organization has established collaborative agreements with institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to further the development of antimalarial drugs. Founded in 1878, the company was initially known as Shionogi Shoten Co., Ltd. before adopting its current designation, Shionogi & Co., Ltd., in 1943. Its corporate operations are based in Osaka, Japan.
businesswire.comNew England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposurebusinesswire.comMay 13
businesswire.comShionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threatsbusinesswire.comApr 8
businesswire.comShionogi Completes Acquisition of All Rights to RADICAVA (edaravone)businesswire.comApr 1
zacks.comSGIOY vs. SDZNY: Which Stock Is the Better Value Option?zacks.comMar 26
businesswire.comShionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Diseasebusinesswire.comMar 19